NewsFeed Voices Science Insight Innovation
Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery
Laura Downey/Children's Healthcare of Atlanta
Aug 15, 2025, 23:32

Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery

Anesthesia and Analgesia shared an insightful post on LinkedIn:

“When compared to cryoprecipitate, can fibrinogen concentrate adequately restore hemostasis and reduce postoperative thrombosis risk in neonates undergoing cardiac surgery with cardiopulmonary bypass (CPB)?

Patients who received fibrinogen concentrate CPB had similar ex vivo clot degradation rates throughout the immediate perioperative period with greater degradation at 24 hours postoperatively and received less post-CPB blood products with no increased risk of bleeding or thrombotic complications when compared to patients who received cryoprecipitate.

Given the increased risks associated with allogenic blood transfusions, our results suggest that fibrinogen concentrate may be a suitable alternative to achieve perioperative hemostasis in neonates undergoing cardiac surgery without increased risk of thrombotic or bleeding complications.”

Read the full article here.

Article: Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery

Authors: Laura A. Downey, Nina Moiseiwitsch, Kimberly Nellenbach, Yijin Xiang, Ashley C. Brown, Nina A.

Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery

Stay updated on the latest scientific advances in the field of clotting disorders with Hemostasis Today.

Anesthesia and Analgesia Ashley C. Brown blood transfusions clot cryoprecipitate Ex Vivo Clot Degradation Fibrinogen Concentrate Health Hematology Hemostasis Today Kimberly Nellenbach Laura A. Downey Medicine Nina A. Nina Moiseiwitsch perioperative hemostasis Yijin Xiang
NewsFeed